Liersch, Torsten

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ruehlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T09:34:12Z"],["dc.date.available","2018-11-07T09:34:12Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32127"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.title","SRC expression in locally advanced rectal cancer-before and after neoadjuvant chemoradiotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","550"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","British Journal of Surgery"],["dc.bibliographiccitation.lastpage","557"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Helms, H.-J."],["dc.contributor.author","Lordick, Florian"],["dc.contributor.author","Rueschoff, Josef"],["dc.contributor.author","Conradi, L.-C."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Thorsten"],["dc.date.accessioned","2018-11-07T09:41:56Z"],["dc.date.available","2018-11-07T09:41:56Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Multidisciplinary discussion of the treatment of patients with colorectal liver metastases (CRLM) is advocated currently. The aim of this study was to investigate medical oncologists' and surgeons' assessment of resectability and indication for chemotherapy, and the effect of an educational intervention on such assessment. Methods: Medical histories of 30 patients with CRLM were presented to ten experienced medical oncologists and 11 surgeons at an initial virtual tumour board meeting (TB1). Treatment recommendations were obtained from each participant by voting for standardized answers. Following lectures on the potential of chemotherapy and surgery, assessment was repeated at a second virtual tumour board meeting (TB2), using the same patients and participants. Results: Overall, 630 answers (21 x 30) were obtained per tumour board meeting. At TB1, resectability was expected more frequently by surgeons. Participants changed 56.8 per cent of their individual answers at TB2. Assessment shifted from potentially resectable to resectable CRLM in 81 of 161 and from unresectable to (potentially) resectable CRLM in 29 of 36 answers. Preoperative chemotherapy was indicated more often by medical oncologists, and overall was included in 260 answers (41.3 per cent) at TB1, compared with only 171 answers (27.1 per cent) at TB2. Medical oncologists more often changed their decision to primary resection in resectable patients (P = 0.006). Postoperative chemotherapy was included in 51.9 and 52.4 per cent of all answers at TB1 and TB2 respectively, with no difference in changes between medical oncologists and surgeons (P = 0.980). Conclusion: Resectability and indication for preoperative chemotherapy were assessed differently by medical oncologists and surgeons. The educational intervention resulted in more patients deemed resectable by both oncologists and surgeons, and less frequent indication for chemotherapy."],["dc.description.sponsorship","Merck Serono GmbH, Germany"],["dc.identifier.doi","10.1002/bjs.9436"],["dc.identifier.isi","000332700100017"],["dc.identifier.pmid","24756914"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33842"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2168"],["dc.relation.issn","0007-1323"],["dc.title","Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Homayonfaur, K."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Yildirim, Muejdat"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T08:55:28Z"],["dc.date.available","2018-11-07T08:55:28Z"],["dc.date.issued","2011"],["dc.format.extent","46"],["dc.identifier.isi","000291236200125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22909"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","17th Annual Meeting of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","A lack of down-regulation of survivin after neoadjuvant Chemoradiotherapy for Rectal cancer with distant metastasis and Reduced survival rate linked"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","27"],["dc.bibliographiccitation.journal","World Journal of Surgical Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:44:09Z"],["dc.date.available","2018-11-07T08:44:09Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. Methods: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival ( OS). Results: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates ( p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum ( ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). Conclusions: Advanced transmural tumor invasion after RCT does not affect prognosis when curative ( R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.1186/1477-7819-8-27"],["dc.identifier.isi","000277431000001"],["dc.identifier.pmid","20388220"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5680"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20132"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7819"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:45:05Z"],["dc.date.available","2018-11-07T09:45:05Z"],["dc.date.issued","2014"],["dc.identifier.isi","000333682100536"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34538"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Gastrointestinal Cancers Symposium"],["dc.relation.eventlocation","San Francisco, CA"],["dc.title","Residual rectal cancer after preoperative radiochemotherapy (ypT1-2): An indication for local excision instead of radical surgery?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","435"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","435 Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of 3/ 3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","54"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Merkel, Susanne"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Raab, Hans-Rudolf"],["dc.contributor.author","Tschmelitsch, Joerg"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:22:42Z"],["dc.date.available","2018-11-07T09:22:42Z"],["dc.date.issued","2013"],["dc.description.abstract","Introduction: The CAO/ARO/AIO-94 phase-III-trial demonstrated a significant improvement of preoperative chemoradiotherapy (CRT) versus postoperative CRT on local control for UICC stage II/III rectal cancer patients, but no effect on long-term survival. In this add-on evaluation, we investigated the association of gender and age with acute toxicity and outcome. Patients and methods: According to actual treatment analyses, 654 of 799 patients had received pre-(n = 406) or postoperative CRT (n = 248); in 145 patients postoperative CRT was not applied. Gender, age and clinicopathological parameters were correlated with CRT-associated acute toxicity and survival. Results: The 10-year survival was higher in women than in men, with 72.4% versus 65.6% for time to recurrence (p = 0.088) and 62.7% versus 58.4% for overall-survival (OS) (p = 0.066), as expected. For patients receiving CRT, women showed higher hematologic (p < 0.001) and acute organ toxicity (p < 0.001) in the entire cohort as well as in subgroup analyses according to pre- (p = 0.016) and postoperative CRT (p < 0.001). Lowest OS was seen in patients without acute toxicity (p = 0.0271). Multivariate analyses for OS showed that acute organ toxicity (p = 0.034) was beneficial while age (p < 0.001) was associated with worse OS. Discussion: Female gender is significantly associated with CRT-induced acute toxicity in rectal cancer. Acute toxicity during CRT may be associated with improved long-term outcome. (C) 2013 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.radonc.2013.05.009"],["dc.identifier.isi","000324155900007"],["dc.identifier.pmid","23768685"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29411"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0167-8140"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S430"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H.A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71771-3"],["dc.identifier.pii","S0959804911717713"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110450"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6126 POSTER Thymidylate Synthase as Biomarker in Rectal Cancer Patients After 5-FU-based Radiochemotherapy – Evaluation of the Prognostic Capacity in Pre-treatment Biopsies and Resected Adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","638"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","649"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:27:25Z"],["dc.date.available","2018-11-07T10:27:25Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-131-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m(2) per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were \"truly adjuvant.\" Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as \"possibly nonadjuvant,\" but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N=5) or relapse (N=14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The \"truly adjuvant\" patients (N=39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P<.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P=.014), and CSS (not reached vs 41.4 months; hazard ratio, 0.42; P=.014) compared with \" possibly nonadjuvant\" patients (N=24). CONCLUSIONS: Repeated RIT with I-131-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for \"truly adjuvant\" patients. However, the maximum safe dose of I-131-labetuzumab is a single administration of 50 millicuries/m(2). (C) 2016 American Cancer Society."],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.identifier.doi","10.1002/cncr.30390"],["dc.identifier.isi","000396841300015"],["dc.identifier.pmid","27763687"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43229"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:19:02Z"],["dc.date.available","2018-11-07T09:19:02Z"],["dc.date.issued","2013"],["dc.format.extent","73"],["dc.identifier.isi","000326360900167"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28546"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0240"],["dc.relation.issn","0378-584X"],["dc.title","5-FU dose monitoring under neoadjuvant radiochemotherapy and adjuvant chemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]